The warrant redemption forces holders to either exercise at $11.00/share (a ~56% discount to the $25.17 VWAP) or receive $0.01 per warrant. Expect near-term dilution as most warrants will be exercised, adding ~$2.1M in cash. The stock's strong performance (VWAP >$22 for 20 days) signals market confidence in the company's nano-PFA technology and atrial fibrillation pipeline. Monitor for any secondary offering or capital deployment plans post-redemption.
Price Chart
Executive Summary
Pulse Biosciences announced it will redeem the remaining 200% Warrants (exercise price $11.00) from its July 2024 rights offering, with a redemption deadline of July 13, 2026. The stock has met the VWAP condition ($25.17 average over 20 consecutive days) to trigger the redemption. The company has already received $63.7M in gross proceeds from prior warrant redemptions and could receive up to an additional $2.1M if all remaining warrants are exercised before the deadline.
Key Facts
- Company delivered irrevocable notice to redeem remaining 200% Warrants (CUSIP 74587B143) issued in July 2024 rights offering
- Redemption deadline: 5:00 p.m. ET on July 13, 2026
- Exercise price: $11.00 per share; redemption price: $0.01 per warrant share
- VWAP condition met: average VWAP of $25.17 over 20 consecutive trading days preceding June 10, 2026
- Aggregate gross proceeds from rights offering: $60 million
- Additional gross proceeds from warrant redemptions to date: $63.7 million
- Potential additional proceeds if remaining warrants exercised: $2.1 million
- First tranche (150% Warrants) redeemed in February 2025; none outstanding
Financial Impact
Up to $2.1M additional cash from warrant exercises; $63.7M already received from prior redemptions; total rights offering + warrant proceeds ~$125.8M
Risk Factors
- Dilution from warrant exercises increases share count
- Potential stock price pressure as warrant holders sell exercised shares
- No guarantee remaining warrants will be exercised before deadline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-020085 |
| Exhibit: ex_973581.htm | 0001437749-26-020085 |
| Document: 0001437749-26-020085-index-headers.html | 0001437749-26-020085 |
| Document: 0001437749-26-020085-index.html | 0001437749-26-020085 |
| Document: 0001437749-26-020085.txt | 0001437749-26-020085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $46.32 | awaiting T+60 | — | $53.19 (+14.84%) |
Oct 7, 2026 20d ago | 8-K | $49.09 | awaiting T+60 | — | $53.19 (+8.36%) |
Sep 15, 2026 6w ago | 8-K | $55.20 | awaiting T+60 | — | $53.19 (−3.63%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $53.19 (−25.43%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $53.19 (−25.43%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $53.19 (+55.31%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $53.19 (+118.28%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $53.19 (+112.87%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $53.19 (+107.71%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $53.19 (+178.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers